As a first-time investor, it can be daunting trying to figure out where to put your money. But don’t worry, we’ve got you covered. Join us as we cover different types of investments!

What are the most popular types of investments? | Get Rich Slow Club

Whilst none of us are the next Warren Buffett, we have the ability to "own a piece of America", as he often suggests. For this reason, we're sharing the 10 most most popular US stocks on Pearler. 

Check out Pearler's most popular US stocks

Think of community data as a compass: you can choose any stock you want, but our community keeps pointing in the same general direction - simple, diversified, and cheap ETFs. Let's take a look at the 10 most popular ETFs on Pearler.

These are Pearler's most popular ETFs

Associated Capital Group Inc (AC:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

Arcosa, Inc. is a provider of infrastructure-related products and solutions with brands serving construction, engineered structure, and transportation markets in North America. The Company’s segments are Construction Products, Engineered Structures and Transportation Products. Its Construction Products segment produces and sells natural and recycled aggregates, specialty materials, and construction site support equipment, including trench shields and shoring products. Its Engineered Structures segment manufactures and sells steel structures for infrastructure businesses, including utility structures for electricity transmission and distribution, structural wind towers, traffic structures, and telecommunication structures. This segment also manufactures distribution tanks. The Transportation Products segment manufactures and sells inland barges, fiberglass barge covers, winches, marine hardware, and steel components for railcars and other transportation and industrial equipment.

Arcosa

Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.

Arbutus Biopharma Corporation

Associated Capital Group, Inc. is a diversified global financial services company. The Company provides alternative investment management services and operates a direct investment business that invests in businesses that fit its criteria. The Company primarily manages assets across a range of risk and event arbitrage portfolios and in equity event-driven value strategies. It conducts its investment management activities through its wholly owned subsidiaries, Gabelli & Company Investment Advisers, Inc. (GCIA) and Gabelli & Partners, LLC (Gabelli & Partners). GCIA and Gabelli & Partners together serve as general partners or investment managers to investment funds, including limited partnerships and offshore companies, and separate accounts. It serves a variety of investors, including private wealth management clients, corporations, corporate pension and profit-sharing plans, foundations and endowments, as well as serving as sub-advisor to certain third-party investment funds.

AC

Buy

👑 Overview

📈

N/A

Annual Growth

🌏

0

Pearlers Invested

Key information

🔎 Fund Overview

Price History*

Unsure how much or often to invest?

🗓️ Investing frequency calculator

💵 Investing amount calculator

⏱️ Investing duration calculator

💵

6.50 AUD*

Purchase Fee

💼

N/A

Management Fee

💸

Want to know the long term costs?

Calculate the historic long term costs to hold your investments

Technical Info

$40.10

How our community is investing

0

N/A

N/A

N/A

N/A

AC investor breakdown

💵 Income of investors

👶 Age of investors

🙋 Legal gender of investors

$67.25 USD

Find Out More

$2.50 USD

Find Out More

Buy